These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 8626121)
1. The association of human papillomavirus type 16 E6 and E7 antibodies with stage of cervical cancer. Fisher SG; Benitez-Bribiesca L; Nindl I; Stockfleth E; Muller M; Wolf H; Perez-Garcia F; Guzman-Gaona J; Gutierrez-Delgado F; Irvin W; Gissmann L Gynecol Oncol; 1996 Apr; 61(1):73-8. PubMed ID: 8626121 [TBL] [Abstract][Full Text] [Related]
2. HPV-16-related proteins as the serologic markers in cervical neoplasia. Park JS; Park DC; Kim CJ; Ahn HK; Um SJ; Park SN; Kim SJ; Namkoong SE Gynecol Oncol; 1998 Apr; 69(1):47-55. PubMed ID: 9570998 [TBL] [Abstract][Full Text] [Related]
3. Absence of antibody against human papillomavirus type 16 E6 and E7 in patients with cervical cancer is independent of sequence variations. Nindl I; Zumbach K; Pawlita M; Teller K; Schneider A; Dürst M J Infect Dis; 2000 May; 181(5):1764-7. PubMed ID: 10783118 [TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus-related serological markers of invasive cervical carcinoma in Brazil. Sun Y; Eluf-Neto J; Bosch FX; Muñoz N; Booth M; Walboomers JM; Shah KV; Viscidi RP Cancer Epidemiol Biomarkers Prev; 1994 Jun; 3(4):341-7. PubMed ID: 8061584 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of antibodies to human papillomavirus as prognostic markers in cervical cancer patients. Silins I; Avall-Lundqvist E; Tadesse A; Jansen KU; Stendahl U; Lenner P; Zumbach K; Pawlita M; Dillner J; Frankendal B Gynecol Oncol; 2002 May; 85(2):333-8. PubMed ID: 11972397 [TBL] [Abstract][Full Text] [Related]
7. In vitro antigene therapy targeting HPV-16 E6 and E7 in cervical carcinoma. Madrigal M; Janicek MF; Sevin BU; Perras J; Estape R; Peñalver M; Averette HE Gynecol Oncol; 1997 Jan; 64(1):18-25. PubMed ID: 8995542 [TBL] [Abstract][Full Text] [Related]
8. Antibodies against linear and conformational epitopes of the human papillomavirus (HPV) type 16 E6 and E7 oncoproteins in sera of cervical cancer patients. Nindl I; Benitez-Bribiesca L; Berumen J; Farmanara N; Fisher S; Gross G; Lopez-Carillo L; Müller M; Tommasino M; Vazquez-Curiel A Arch Virol; 1994; 137(3-4):341-53. PubMed ID: 7524466 [TBL] [Abstract][Full Text] [Related]
9. Correlation between serological immune response analyzed by a new ELISA for HPV-16/18 E7 oncoprotein and clinical characteristics of cervical cancer patients. Ravaggi A; Romani C; Pasinetti B; Tassi RA; Bignotti E; Bandiera E; Odicino FE; Ragnoli M; Donzelli C; Falchetti M; Calza S; Santin AD; Pecorelli S Arch Virol; 2006 Oct; 151(10):1899-916. PubMed ID: 16732494 [TBL] [Abstract][Full Text] [Related]
10. Identification of E6/E7 transcription patterns in HPV 16-positive cervical cancers using the reverse transcription/polymerase chain reaction. Rose BR; Thompson CH; Tattersall MH; Elliott PM; Dalrymple C; Cossart YE Gynecol Oncol; 1995 Feb; 56(2):239-44. PubMed ID: 7896192 [TBL] [Abstract][Full Text] [Related]
11. Serological study in Tunisian cervical cancer patients. Achour M; Kochbati L; Zeghal D; Kahla S; Maalej M; Zouari F; Oueslati R Pathol Biol (Paris); 2009 Jul; 57(5):415-9. PubMed ID: 18586408 [TBL] [Abstract][Full Text] [Related]
12. Relation between HPV-16 serology and clinico-pathological data in cervical carcinoma patients: prognostic value of anti-E6 and/or anti-E7 antibodies. Baay MF; Duk JM; Groenier KH; Burger MP; de Bruijn HW; Hollema H; Stolz E; Herbrink P Cancer Immunol Immunother; 1997 Jun; 44(4):211-5. PubMed ID: 9222279 [TBL] [Abstract][Full Text] [Related]
13. High human papillomavirus oncogene mRNA expression and not viral DNA load is associated with poor prognosis in cervical cancer patients. de Boer MA; Jordanova ES; Kenter GG; Peters AA; Corver WE; Trimbos JB; Fleuren GJ Clin Cancer Res; 2007 Jan; 13(1):132-8. PubMed ID: 17200347 [TBL] [Abstract][Full Text] [Related]
14. Immunological responses in human papillomavirus 16 E6/E7-transgenic mice to E7 protein correlate with the presence of skin disease. Frazer IH; Leippe DM; Dunn LA; Liem A; Tindle RW; Fernando GJ; Phelps WC; Lambert PF Cancer Res; 1995 Jun; 55(12):2635-9. PubMed ID: 7540107 [TBL] [Abstract][Full Text] [Related]
15. The presence of human papillomavirus-16/-18 E6, p53, and Bcl-2 protein in cervicovaginal smears from patients with invasive cervical cancer. Pillai MR; Halabi S; McKalip A; Jayaprakash PG; Rajalekshmi TN; Nair MK; Herman B Cancer Epidemiol Biomarkers Prev; 1996 May; 5(5):329-35. PubMed ID: 9162297 [TBL] [Abstract][Full Text] [Related]
16. [Detection of high-risk human papillomavirus (HPV) E6 and E7 oncogene transcripts increases the specificity of the detection of a cervical intraepithelial neoplasia (CIN)]. Sotlar K; Diemer D; Stubner A; Menton S; Menton M; Dietz K; Wallwiener D; Bültmann B Verh Dtsch Ges Pathol; 2005; 89():195-200. PubMed ID: 18035691 [TBL] [Abstract][Full Text] [Related]
17. Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in cervical-carcinoma patients from Russia. Zumbach K; Kisseljov F; Sacharova O; Shaichaev G; Semjonova L; Pavlova L; Pawlita M Int J Cancer; 2000 Feb; 85(3):313-8. PubMed ID: 10652419 [TBL] [Abstract][Full Text] [Related]
18. [Human papilloma virus and cervical cancer]. Kawana T Gan To Kagaku Ryoho; 1995 May; 22(6):711-7. PubMed ID: 7755378 [TBL] [Abstract][Full Text] [Related]
19. Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep Papanicolaou tests using real-time polymerase chain reaction analysis. Wang-Johanning F; Lu DW; Wang Y; Johnson MR; Johanning GL Cancer; 2002 Apr; 94(8):2199-210. PubMed ID: 12001118 [TBL] [Abstract][Full Text] [Related]
20. Antibodies against human papillomavirus (HPV) type 16 and 18 E2, E6 and E7 proteins in sera: correlation with presence of papillomavirus DNA. Rosales R; López-Contreras M; Cortes RR J Med Virol; 2001 Dec; 65(4):736-44. PubMed ID: 11745939 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]